REGN

Regeneron Pharmaceuticals Inc

807.48

Oct 20 • 3:59 PM ET +25.44 (3.25%)

805.52

Aftermarket • 7:03 PM ET -1.96 (-0.24%)

Healthcare Biotechnology USA Large NASD

Peers: VRTX AMGN ALNY ARGX SNY GILD BIIB MRNA ABBV BMY

| Held by: VTI VOO QQQ IVV SPY VO VTV IBB XLV JEPI

Scroll to Statements

Index	NDX, S&P 500
Market Cap	83.13B
Enterprise Value	77.84B
Income	4.33B
Sales	15.53B
Book/sh	306.69
Cash/sh	77.75
Dividend Est.	3.54 (0.44%)
Dividend TTM	3.70 (0.46%)
Dividend Ex-Date	Aug 18, 2026
Dividend Gr. 3/5Y	- -
Payout	8.49%
Employees	15410
IPO	Apr 02, 1991

P/E	19.96
Forward P/E	12.91
PEG	0.79
P/S	5.35
P/B	2.63
P/C	10.39
P/FCF	22.11
EV/EBITDA	16.55
EV/Sales	5.01
Quick Ratio	2.78
Current Ratio	3.34
Debt/Eq	0.09
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	40.46
EPS next Y	62.57
EPS next Q	16.12
EPS this Y	33.62%
EPS next Y	5.68%
EPS next 5Y	16.34%
EPS past 3/5Y	2.76% 6.33%
Sales past 3/5Y	5.62% 11.04%
EPS Y/Y TTM	0.38%
Sales Y/Y TTM	9.29%
EPS Q/Q	-4.52%
Sales Q/Q	16.73%
Earnings	Oct 30 BMO
EPS/Sales Surpr.	40.69% 12.40%

Insider Own	3.78%
Insider Trans	-0.22%
Inst Own	91.58%
Inst Trans	-0.39%
ROA	10.83%
ROE	14.04%
ROIC	12.85%
Gross Margin	81.46%
Oper. Margin	26.87%
Profit Margin	27.86%
SMA20	5.68%
SMA50	2.11%
SMA200	9.77%
Trades

Shs Outstand	101.60M
Shs Float	99.07M
Short Float	2.17%
Short Ratio	2.91
Short Interest	2.15M
52W High	859.34 -6.03%
52W Low	572.75 40.98%
Volatility	2.68% 2.80%
ATR (14)	21.87
RSI (14)	60.89
Beta	0.13
Rel Volume	0.84
Avg Volume	739.94K
Volume	623,401

Perf Week	7.22%
Perf Month	1.17%
Perf Quarter	24.00%
Perf Half Y	8.04%
Perf YTD	4.61%
Perf Year	40.00%
Perf 3Y	-0.12%
Perf 5Y	43.50%
Perf 10Y	117.51%
Recom	1.87
Target Price	869.92
Prev Close	782.04
Price	807.48
Change %	3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-26	Upgrade	Argus	Hold → Buy	$850
May-18-26	Downgrade	Leerink Partners	Outperform → Market Perform	$641
May-18-26	Downgrade	Citigroup	Buy → Neutral	$700
Mar-31-26	Resumed	Piper Sandler	Overweight	$875
Mar-06-26	Initiated	Barclays	Overweight	$923
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy	$860
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$767
Nov-24-25	Resumed	Truist	Buy	$798
Nov-24-25	Initiated	HSBC Securities	Buy	$255
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150

Show Previous Ratings

Today 07:37AM	EyePoint halves workforce and ends Phase III trial early after endpoint miss (Clinical Trials Arena)
Oct-16-26 07:00AM	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types (GlobeNewswire)
Oct-14-26 05:45PM	What Could Send Regeneron Stock Higher? (Trefis)
07:34AM	Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight (Investor's Business Daily)
Oct-13-26 07:00AM	Regeneron reports 84-week Phase III data for Pasatru in adult FOP (Clinical Trials Arena)
01:41PM	Loading…
Oct-12-26 01:41PM	Regenerons Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial REGN Stock Heads For Best Day In Over A Month (Stocktwits)
12:06PM	Pasatru (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension (GlobeNewswire)
Oct-09-26 11:36AM	Is Vertex Stock Worth More Than Its Competitors? (Trefis)
Oct-08-26 08:19PM	What Is Going On With Regeneron Stock? (Trefis)
Oct-06-26 07:00AM	Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 (GlobeNewswire)
Oct-02-26 08:13PM	Stocktwits Biotech Dealmaker Novartis, Sanofi And Novo Sign Weeks Biggest Deals (Stocktwits)
11:00AM	This week in charts: Kodiaks big comeback and Hengruis dealmaking (BioPharma Dive)
08:26AM	Sanofi pays Regeneron up to $8B to expand immunology alliance (Quartz)
Oct-01-26 05:35PM	OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD (Stocktwits)
11:38AM	Sanofi, Regeneron broaden alliance to find their next Dupixent (BioPharma Dive)
11:35AM	Loading…
11:35AM	Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) (GlobeNewswire)
11:30AM	Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss (GlobeNewswire)
09:38AM	Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls (The Fly)
07:40AM	Sanofi and Regeneron expand immunology partnership to the tune of $8bn (Pharmaceutical Technology)
07:36AM	Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights (Stocktwits)
02:27AM	Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion (The Wall Street Journal)
02:00AM	Sanofi gains after expanding Regeneron partnership with $8 billion deal (Investing.com)
01:00AM	Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies (GlobeNewswire)
Sep-30-26 08:03AM	MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum (Stocktwits)
Sep-28-26 10:13PM	KOD Stock Cracks Septembers Top 5 Biotech Gainers On Eye Drug Win But Pharma Bro Shkreli Says It Still Sucks (Stocktwits)
04:14PM	Why This Regeneron Eye Rival Just Catapulted More Than 170% (Investor's Business Daily)
01:35PM	Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron's (The Wall Street Journal)
01:15PM	OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits)
12:11PM	Kodiak skyrockets on positive study data for 2 eye drugs (BioPharma Dive)
12:09PM	Kodiaks stock rallies on Phase III wAMD success (Clinical Trials Arena)
07:31AM	Loading…
07:31AM	Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial (Barrons.com)
Sep-24-26 04:05PM	Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 (GlobeNewswire)
Sep-16-26 02:33PM	ALVO Stock Jumps On Double Upgrade Why Barclays Sees A 59% Upside (Stocktwits)
12:24PM	Why This Biotech Stock Just Got a Rare Double Upgrade (Barrons.com)
Sep-04-26 08:00AM	Trailing rivals, AbbVie scores win with dual-acting myeloma drug (BioPharma Dive)
Aug-21-26 04:39AM	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
Aug-20-26 01:26PM	How Moderna's Historic Short Squeeze Upended the AI Chip Trade (Barrons.com)
08:21AM	Regeneron to challenge Ipsen as FDA clears bone disease drug (BioPharma Dive)
Aug-19-26 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
01:58PM	Pasatru (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP) (GlobeNewswire)
10:44AM	Biotech Stocks Are Booming. What This Top Fund Is Buying Now. (Barrons.com)
06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
Aug-18-26 10:40AM	EyePoints Duravyu falls short to Eylea in Phase III trial (Clinical Trials Arena)
Aug-17-26 11:14AM	EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. (Barrons.com)
Aug-14-26 05:51AM	BMS builds big in Texas; Regeneron backs would-be rival (Pharma Voice)
Aug-12-26 07:16AM	Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs (Pharmaceutical Technology)
Aug-06-26 03:03PM	Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... (GuruFocus.com)
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
08:36AM	AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps (The Wall Street Journal)
07:06AM	Sanofi to rebuild trust with Regeneron; Apnimed adds to string of upsized biotech IPOs (BioPharma Dive)
07:00AM	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation (GlobeNewswire)
Jul-30-26 05:04PM	Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ... (GuruFocus.com) +6.17%
10:00AM	Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results (InvestorsHub)
07:59AM	Regeneron beats quarterly estimates on eczema drug strength, shares rise (Reuters)
06:47AM	Regeneron: Q2 Earnings Snapshot (Associated Press)
06:30AM	Regeneron Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire)
01:44AM	Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline (The Wall Street Journal)
Jul-24-26 01:40PM	The Scientist With 1,000 Patents Fueling a Drug Powerhouse (The Wall Street Journal)
Jul-23-26 10:00AM	Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN (Newsfile)
Jul-20-26 03:00AM	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
Jul-18-26 11:30AM	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights REGN (Business Wire)
Jul-17-26 06:39AM	The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea (Yahoo Finance)
Jul-16-26 09:13AM	Dow Jones' Merck Snags A First-Of-Its-Kind Approval, And Jumps (Investor's Business Daily)
09:06AM	Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
08:17AM	Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill (Barrons.com)
06:45AM	Merck Gets Approval for Powerful Cholesterol-Cutting Pill (Barrons.com)
Jul-15-26 01:20PM	Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings (Barrons.com)
Jul-13-26 01:37PM	Own Regeneron For Biotech Growth? Incyte Is Making Its Case. (Trefis)
Jul-08-26 11:00AM	23andMe data breach victims win court approval for $46.75 million settlement (Quartz)
08:48AM	Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jun-30-26 11:31AM	Lilly and Regeneron amongst first incumbents to FDAs fast-track facility scheme (Pharmaceutical Technology)
07:10AM	FDA PreCheck pilot program selects Eli Lilly, Regeneron (Quartz)
06:53AM	Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger (Pharmaceutical Technology)
Jun-26-26 07:00AM	From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak (Newsfile)
Jun-25-26 04:05PM	Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast (GlobeNewswire)
11:16AM	Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi? (Investor's Business Daily)
Jun-22-26 02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
09:08AM	Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics (Barrons.com)
07:42AM	AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash (The Wall Street Journal)
07:00AM	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis)
Jun-11-26 07:29AM	Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy (BioPharma Dive)
Jun-10-26 03:52PM	Parabilis Raises Nearly $745 Million As IPO Demand Surges (GuruFocus.com)
12:21PM	Parabilis Medicines raises record $670 million in biotech IPO (Quartz)
07:06AM	Parabilis sets a record with a $670M biotech IPO (BioPharma Dive)
Jun-05-26 06:54AM	Parabilis eyes $475m IPO to push lead asset into Phase III (Pharmaceutical Technology)
Jun-04-26 07:00AM	Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO (GlobeNewswire)
05:21AM	Regeneron and CytomX extend cancer therapy partnership to $4bn deal (Pharmaceutical Technology)
Jun-03-26 07:15AM	NewLimits $435M megaround; Lillys busy dealmaking week (BioPharma Dive)
May-28-26 04:00PM	Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak (GlobeNewswire)
May-22-26 07:00AM	Otarmeni (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss (GlobeNewswire)
May-21-26 05:01PM	Lynozyfic (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis (GlobeNewswire)
May-20-26 01:54PM	ATS 2026: Mixed results for Sanofi/Regenerons itepekimab cloud COPD prospects (Clinical Trials Arena)
07:58AM	After raising $800M, Parabilis seeks an IPO to pursue undruggable targets (BioPharma Dive)
May-19-26 06:16AM	Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates (Pharmaceutical Technology)
May-18-26 03:40PM	U.S. plans to move physicians exposed to rare Ebola virus to Germany (MarketWatch) -9.82%
10:17AM	Regeneron Stock Tumbles on Melanoma Drug Trial Miss (The Wall Street Journal)
10:05AM	Regeneron drops after skin cancer treatment fails late-stage trial (Reuters)
09:55AM	Zscaler upgraded, CoreWeave downgraded: Wall Street's top analyst calls (The Fly)
09:26AM	The Surprising Reason Regeneron Pharmaceuticals Just Dropped 12% (Investor's Business Daily)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MURPHY ANDREW J	Co-Chief Scientific Officer	Oct 13 '26	Option Exercise	381.92	17,000	6,492,640	64,833	Oct 15 04:02 PM
MURPHY ANDREW J	Co-Chief Scientific Officer	Oct 14 '26	Sale	772.70	4,147	3,204,376	47,833	Oct 15 04:02 PM
MURPHY ANDREW J	Officer	Oct 14 '26	Proposed Sale	772.70	4,147	3,204,380		Oct 14 04:04 PM
McCourt Marion	EVP Commercial	Sep 02 '26	Sale	850.00	1,215	1,032,750	13,134	Sep 03 04:50 PM
McCourt Marion	EVP Commercial	Sep 03 '26	Sale	857.39	1,131	969,708	12,003	Sep 03 04:50 PM
Guarini Kathryn	Director	Sep 02 '26	Option Exercise	719.37	400	287,748	1,003	Sep 03 04:47 PM
Guarini Kathryn	Director	Sep 02 '26	Sale	850.00	400	340,000	603	Sep 03 04:47 PM
McCourt Marion	Officer	Sep 03 '26	Proposed Sale	857.00	1,131	969,267		Sep 03 04:07 PM
McCourt Marion	Officer	Sep 02 '26	Proposed Sale	850.00	1,215	1,032,750		Sep 02 04:11 PM
Guarini Kathryn	Director	Sep 02 '26	Proposed Sale	850.00	400	340,000		Sep 02 04:09 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 19 '26	Option Exercise	381.92	12,282	4,690,741	45,392	Aug 21 04:01 PM
Fenimore Christopher R.	EVP Finance CFO	Aug 18 '26	Option Exercise	381.92	6,283	2,399,603	24,583	Aug 20 04:01 PM
Guarini Kathryn	Director	Aug 10 '26	Option Exercise	719.37	400	287,748	1,003	Aug 12 04:16 PM
Guarini Kathryn	Director	Aug 10 '26	Sale	800.00	400	320,000	603	Aug 12 04:16 PM
Zoghbi Huda Y	Director	Aug 10 '26	Option Exercise	376.69	800	301,352	2,503	Aug 12 04:14 PM
Zoghbi Huda Y	Director	Aug 10 '26	Sale	800.00	800	640,000	1,703	Aug 12 04:14 PM
Zoghbi Huda Y	Director	Aug 10 '26	Proposed Sale	800.00	800	640,000		Aug 10 04:14 PM
Guarini Kathryn	Board member	Aug 10 '26	Proposed Sale	800.00	400	320,000		Aug 10 04:11 PM
RYAN ARTHUR F	Director	Jul 02 '26	Sale	650.15	200	130,030	17,303	Jul 07 04:05 PM
Arthur F. Ryan	Director	Jul 02 '26	Proposed Sale	624.72	400	249,888		Jul 02 05:46 PM
RYAN ARTHUR F	Director	May 01 '26	Sale	705.24	100	70,524	17,503	May 04 04:14 PM
RYAN ARTHUR F	Director	Apr 01 '26	Sale	777.27	100	77,727	17,603	Apr 03 04:01 PM
RYAN ARTHUR F	Director	Mar 02 '26	Sale	785.50	100	78,550	17,703	Mar 03 04:01 PM
Zoghbi Huda Y	Director	Feb 19 '26	Option Exercise	376.69	1,638	617,018	3,341	Feb 23 04:55 PM
Zoghbi Huda Y	Director	Feb 19 '26	Sale	781.33	1,638	1,279,812	1,703	Feb 23 04:55 PM
Zoghbi Huda Y	Director	Feb 19 '26	Proposed Sale	790.00	1,638	1,294,020		Feb 19 04:04 PM
Pitofsky Jason	SVP Controller	Feb 09 '26	Option Exercise	492.00	1,000	492,000	6,308	Feb 11 04:03 PM
Pitofsky Jason	SVP Controller	Feb 09 '26	Sale	778.52	2,036	1,585,058	4,272	Feb 11 04:03 PM
RYAN ARTHUR F	Director	Feb 09 '26	Sale	778.53	100	77,853	17,803	Feb 11 04:02 PM
Arthur F. Ryan	Director	Feb 09 '26	Proposed Sale	785.51	400	314,204		Feb 09 05:02 PM
Pitofsky Jason	Officer	Feb 09 '26	Proposed Sale	783.17	2,036	1,594,534		Feb 09 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Option Exercise	374.12	1,500	561,180	3,203	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Sale	800.00	1,500	1,200,000	1,703	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Proposed Sale	800.00	1,500	1,200,000		Jan 07 12:03 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 31 '25	Option Exercise	0.00	28,570	0	339,030	Jan 05 05:54 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 31 '25	Option Exercise	0.00	28,570	0	243,093	Jan 05 05:53 PM
SING GEORGE L	Director	Dec 30 '25	Option Exercise	520.01	9,212	4,790,332	37,040	Dec 31 05:05 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 09 '25	Option Exercise	555.67	146,815	81,580,691	442,334	Dec 11 04:27 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 09 '25	Option Exercise	555.67	172,723	95,976,989	369,668	Dec 11 04:23 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Nov 20 '25	Option Exercise	555.67	14,450	8,029,431	35,525	Nov 24 04:07 PM
Bassler Bonnie L	Director	Nov 20 '25	Option Exercise	371.40	760	282,264	2,308	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Sale	750.00	760	570,000	1,548	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Ph.D.Dr. Leonard S. Schleifer M.D.

Ph.D.Dr. George D. Yancopoulos M.D.

Executive VP of Finance & CFOMr. Christopher R. Fenimore CPA

Executive VPMr. Joseph J. LaRosa J.D.

Executive VP of Research & Co-Chief Scientific OfficerDr. Andrew J. Murphy Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals Inc

Upgrade your Finviz experience